Novo has struck a 1.17 billion euro ($1.3 billion) deal to combine Nanexa’s long-acting injectable drug delivery platform ...
Roche’s Genentech is paying Earendil Labs $55 million upfront to discover and develop multiple bispecific antibodies. The ...
Ahead of its upcoming merger with Supernus, Indivior Pharmaceuticals has ended its long-running collaboration with Addex Therapeutics to develop positive allosteric modulators (PAMs). Their ...
ADARx Pharmaceuticals has overshot its own IPO ambitions, as fellow RNA-focused biotech City Therapeutics also plans a public ...
Welcome to this week's Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the ...
Overton conceded multiple times during the hearing that vaccines approved by the FDA, as well as the so-called “abortion pill ...
Eli Lilly has committed $100 million in upfront and near-term payments to InnoCare Pharma to form a five-target drug ...
Acadia Pharmaceuticals’ phase 2 Alzheimer’s disease trial has missed its primary endpoint, but the company and analysts alike ...
The National Institutes of Health's National Library of Medicine has released the pilot version of a new tool designed to ...
Boehringer Ingelheim has dived deeper into its collaboration with Variant Bio by expanding the collaboration to cover ...
Immunovant has stopped development of IMVT-1402 in cutaneous lupus erythematosus after failing a midphase test, closing off ...
Kyverna ‘resetting conversation’ with 1-year miv-cel data as autoimmune CAR-T peers hit safety snags
As two Big Pharma players in the autoimmune CAR-T space face unexpected safety setbacks, Kyverna Therapeutics is reporting long-term clinical data that showcase sustained efficacy alongside an ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results